These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 37942961)

  • 1. Fluorescent Tools for the Imaging of Dopamine D
    Nagl M; Mönnich D; Rosier N; Schihada H; Sirbu A; Konar N; Reyes-Resina I; Navarro G; Franco R; Kolb P; Annibale P; Pockes S
    Chembiochem; 2024 Jan; 25(2):e202300659. PubMed ID: 37942961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Shedding Light on the D
    Rosier N; Mönnich D; Nagl M; Schihada H; Sirbu A; Konar N; Reyes-Resina I; Navarro G; Franco R; Kolb P; Annibale P; Pockes S
    Chembiochem; 2024 Jan; 25(2):e202300658. PubMed ID: 37983731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, in silico, and in vitro studies of novel dopamine D
    Elek M; Djokovic N; Frank A; Oljacic S; Zivkovic A; Nikolic K; Stark H
    Arch Pharm (Weinheim); 2021 Jun; 354(6):e2000486. PubMed ID: 33615541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro pharmacological profile of YM-43611, a novel D2-like receptor antagonist with high affinity and selectivity for dopamine D3 and D4 receptors.
    Hidaka K; Tada S; Matsumoto M; Ohmori J; Tasaki Y; Nomura T; Usuda S; Yamaguchi T
    Br J Pharmacol; 1996 Apr; 117(8):1625-32. PubMed ID: 8732269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of [125I]S(-)5-OH-PIPAT binding to dopamine D2-like receptors expressed in cell lines.
    Vessotskie JM; Kung MP; Chumpradit S; Kung HF
    Neuropharmacology; 1997 Jul; 36(7):999-1007. PubMed ID: 9257944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine D2-like receptors on human peripheral blood lymphocytes: a radioligand binding assay and immunocytochemical study.
    Amenta F; Bronzetti E; Felici L; Ricci A; Tayebati SK
    J Auton Pharmacol; 1999 Jun; 19(3):151-9. PubMed ID: 10511471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple fluorescent ligands for dopamine receptors. I. Pharmacological characterization and receptor selectivity.
    Barton AC; Kang HC; Rinaudo MS; Monsma FJ; Stewart-Fram RM; Macinko JA; Haugland RP; Ariano MA; Sibley DR
    Brain Res; 1991 May; 547(2):199-207. PubMed ID: 1679366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and structure-activity relationships of naphthamides as dopamine D3 receptor ligands.
    Huang Y; Luedtke RR; Freeman RA; Wu L; Mach RH
    J Med Chem; 2001 May; 44(11):1815-26. PubMed ID: 11356115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and characterization of selective dopamine D2 receptor antagonists.
    Vangveravong S; McElveen E; Taylor M; Xu J; Tu Z; Luedtke RR; Mach RH
    Bioorg Med Chem; 2006 Feb; 14(3):815-25. PubMed ID: 16288878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of [(3) H]LS-3-134, a novel arylamide phenylpiperazine D3 dopamine receptor selective radioligand.
    Rangel-Barajas C; Malik M; Taylor M; Neve KA; Mach RH; Luedtke RR
    J Neurochem; 2014 Nov; 131(4):418-31. PubMed ID: 25041389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.
    Grundt P; Carlson EE; Cao J; Bennett CJ; McElveen E; Taylor M; Luedtke RR; Newman AH
    J Med Chem; 2005 Feb; 48(3):839-48. PubMed ID: 15689168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antagonist properties of LY 165,163 at pre- and postsynaptic dopamine D2, D3 and D1 receptors: modulation of agonist actions at 5-HT1A receptors in vivo.
    Millan MJ; Rivet JM; Audinot V; Gobert A; Lejeune F; Brocco M; Newman-Tancredi A; Maurel-Remy S; Bervoets K
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1418-27. PubMed ID: 7791116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and pharmacological characterization of [125I]L-750,667, a novel radioligand for the dopamine D4 receptor.
    Patel S; Patel S; Marwood R; Emms F; Marston D; Leeson PD; Curtis NR; Kulagowski JJ; Freedman SB
    Mol Pharmacol; 1996 Dec; 50(6):1658-64. PubMed ID: 8967990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional and autoradiographic characterization of dopamine D2-like receptors in the guinea pig heart.
    Gómez Mde J; Rousseau G; Nadeau R; Berra R; Flores G; Suárez J
    Can J Physiol Pharmacol; 2002 Jun; 80(6):578-87. PubMed ID: 12117307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the binding and functional properties of two structurally different D2 dopamine receptor subtype selective compounds.
    Luedtke RR; Mishra Y; Wang Q; Griffin SA; Bell-Horner C; Taylor M; Vangveravong S; Dillon GH; Huang RQ; Reichert DE; Mach RH
    ACS Chem Neurosci; 2012 Dec; 3(12):1050-62. PubMed ID: 23259040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of 50-kHz ultrasonic vocalizations by dopamine receptor subtype-selective agonists and antagonists in adult rats.
    Scardochio T; Clarke PB
    Psychopharmacology (Berl); 2013 Apr; 226(3):589-600. PubMed ID: 23192317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Dopamine D2 Receptor Agonist, [
    Subburaju S; Sromek AW; Seeman P; Neumeyer JL
    ACS Chem Neurosci; 2018 Jun; 9(6):1283-1289. PubMed ID: 29641175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the binding of SCH 39166 to the five cloned dopamine receptor subtypes.
    Tice MA; Hashemi T; Taylor LA; Duffy RA; McQuade RD
    Pharmacol Biochem Behav; 1994 Nov; 49(3):567-71. PubMed ID: 7862709
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.